Our data support the hypothesis that cancer cells may undergo adaptive changes after anti-tumor therapies (either chemotherapy or targeted therapy) and also demonstrate that the IL-6/STAT3/Jagged-1/Notch signaling pathway exerts critical functions in trastuzumab resistant gastric cancer cells. Here, JAG1 is linked to gastric cancer.